Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To develop a disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (DSI-ARSACS) that considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and to document its content validity, internal consistency, and construct validity.
Methods The Beta DSI-ARSACS (17 items) was developed based on literature review and expert inputs and then administered to 26 participants. Items reduction was based on Cronbach α and desirable criteria. Performance measures were administered to assess the construct validity of the final version of the DSI-ARSACS.
Results The final DSI-ARSACS have 8 items that can be easily performed during usual medical follow-up. The mean score was 19.6 ± 8.1 (range 6.0–35.5) and the Cronbach α was 0.912. The DSI-ARSACS score increased with disease stage and age (p ≤ 0.001) and was closely correlated with other measures assessing similar construct (9-Hole Peg Test, 10-Meter Walk Test, Scale for the Assessment and Rating of Ataxia, Berg Balance Scale, Barthel Index) (rs = 0.75–0.95, p < 0.01). A moderate but not significant correlation was found with the 6-Minute Walk test (rs = −0.611, p = 0.108).
Conclusions The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles. Further documentation of metrologic properties is necessary, but these first results are promising.
Glossary
- 6MWT=
- 6-Minute Walk Test;
- 9HPT=
- 9-Hole Peg Test;
- 10MWT=
- 10-Meter Walk Test;
- ARSACS=
- autosomal recessive spastic ataxia of Charlevoix-Saguenay;
- BBS=
- Berg Balance Scale;
- CIUSSS-SLJS=
- Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay Lac-St-Jean;
- DSI-ARSACS=
- disease-specific severity index for autosomal recessive spastic ataxia of Charlevoix-Saguenay;
- SARA=
- Scale for the Assessment and Rating of Ataxia;
- SF-12=
- 12-Item Short-Form Health Survey
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received November 23, 2018.
- Accepted in final form May 15, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
An exploratory natural history of ataxia of Charlevoix-SaguenayA 2-year follow-upCynthia Gagnon, Isabelle Lessard, Caroline Lavoie et al.Neurology, August 29, 2018 -
Review
Three Adult-Onset Autosomal Recessive AtaxiasWhat Adult Neurologists Need to KnowJordan A. Paulus-Andres, Melinda S. Burnett et al.Neurology: Clinical Practice, September 15, 2020 -
Articles
Mutations in SACS cause atypical and late-onset forms of ARSACSJ. Baets, T. Deconinck, K. Smets et al.Neurology, September 27, 2010 -
Brief Communications
Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay typeG. S. Grieco, A. Malandrini, G. Comanducci et al.Neurology, January 12, 2004